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I. INTRODUCTION
Between 1975 and 2003, nearly half a million women forty years of age
and older were diagnosed with breast cancer in the United States.1 Early
diagnosis can allow women who are genetically predisposed to breast
cancer to take preventive measures and reduce their risks of cancer by as
much as ninety percent.2 In 1994, Myriad Genetics isolated and sequenced
a breast cancer susceptibility gene and subsequently developed a test that
allows women to determine whether they are at risk.3 Because of the
extensive time, money, and energy Myriad placed into its research, women
can determine their susceptibility, and possibly even diagnose the cancer, at
earlier stages.4 As a reward for its efforts, Myriad received patents on the
isolated gene sequences and breast cancer predisposition testing method,
and these patents are now the subjects of contentious litigation.5
1. See Ahmedin Jemal, et al., Recent Trends in Breast Cancer Incidence Rates by
Age and Tumor Characteristics Among U.S. Women, Breast Cancer Research, 3 (May
3, 2007), http://breast-cancer-research.com/content/pdf/bcr1672 (illustrating that
394,891 of breast-cancer diagnoses were invasive breast cancer while 59,837 were in
situ breast cancer).
2. Myriad Genetics, Why Take a Breast/Ovarian Cancer Risk Assessment Test?,
BRACANALYSIS,
http://www.bracnow.com/considering-testing/why-take-a-breastovarian-cancer-risk-test.php.
3. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181, 201 (S.D.N.Y. 2010) (noting that researchers first discovered the gene’s
existence on chromosome seventeen in 1990).
4. See id. at 203 (illustrating that women with the breast cancer mutation have an
eighty-five percent chance of developing breast cancer and a fifty percent chance of
developing ovarian cancer).
5. See id. at 185-86 (contending that gene patents issued to Myriad Genetics for a
breast cancer susceptibility gene are unpatentable because they are laws of nature).
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Scientific opponents of Myriad’s patents argue that its exclusive licenses
on the gene sequences and predictive testing hinder research because other
institutions cannot continue research on the gene or second-guess Myriad’s
tests.6 Legal opponents assert that these isolated sequences are laws of
nature and, thus, unpatentable subject matter.7 Nevertheless, the driving
force behind both arguments is the notion that Myriad should not be
rewarded for winning the race because other research institutions were
equally capable of isolating and sequencing the gene.8 Patent law,
however, was not developed under principles of fairness or equality.9
The concept that researchers should be rewarded for their ingenuity in
furtherance of societal good is at the heart of patent law.10 The patent is the
reward, and as such, it provides the impetus for researchers to receive
funding for their work.11 Currently, 6,000 gene sequences are the subjects
of patents, thereby demonstrating the success of patent law in accelerating
research in the field.12 Eliminating genetic researchers’ ability to patent
isolated gene sequences will destroy the incentives that led to their
successes in the first place.13
This Comment argues that the Southern District of New York’s decision
invalidating Myriad’s patents claiming isolated breast-cancer gene
sequences and breast-cancer predisposition tests is erroneous as a matter of

6. Cf. David C. Hoffman, Note, A Modest Proposal: Toward Improved Access to
Biotechnology Research Tools by Implementing a Broad Experimental Use Exception,
89 CORNELL L. REV. 993, 1038 (2004) (describing patents’ inhibitive effects on
subsequent research).
7. See Jennifer Giordano-Coltart, et al., No Legal Monopoly for Genes: Court
Rules Genes Are Unpatentable Subject Matter, 22 INTELL. PROP. & TECH. L.J. 8, 9-10
(2010) (emphasizing the scientific community’s anger with Myriad’s refusal to share
data or license the patents).
8. See Hoffman, supra note 6, at 1023 (discussing patents’ triggering effects on
the race to invent in the biotechnology industry).
9. Cf. id. at 1023-24 (illustrating that, in the race triggered by patents, no prize
exists for second place).
10. See, e.g., Melissa Wetkowski, Note, Unfitting: Gene Patent Limitations Too
Tight for United States’ Biotechnology Innovation and Growth in Light of International
Patenting Policies, 16 SW. J. INT’L L. 181, 182 (2010) (arguing that a ban on gene
patents effectively destroys research incentives).
11. See, e.g., id. (asserting that patents create assurances of stability, such that
patents have meaning and stability of enforcement to incentivize research).
12. See Lauren M. Nowierski, Note, A Defense of Patenting Human Gene
Sequences Under U.S. Law: Support for the Patenting of Isolated and Purified
Substances, 26 CARDOZO ARTS & ENT. L.J. 473, 475 (2008) (adding that the Human
Genome Project also led to an increase in gene patents).
13. See Lisa Larrimore Ouellette, Note, Access to Bio-Knowledge: From Gene
Patents to Biomedical Materials, 2010 STAN. TECH. L. REV. N.1 (2010), available at
http://stlr.stanford.edu/pdf/ouellette-access-to-bio-knowledge.pdf (depicting studies
that suggest gene patents are not impediments, and that access to materials is a larger
obstacle).
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law and policy.14 Part II explains the development of the legal standards
defining patentable subject matter and describes the basis on which the
Southern District of New York reached its holding.15 Part III argues that
the Southern District of New York’s holding is erroneous as a matter of
law.16 Part IV of this Comment presents sound policy considerations in
favor of patenting genes and recommends a research exemption to gene
patents.17 Finally, Part V concludes that prohibiting gene patents destroys
the rewards of patent law that promote scientific research.18
II. BACKGROUND
A. Origins of Patentability in the United States
Article I, section 8, clause 8 of the U.S. Constitution confers upon
Congress the authority to grant patents.19 Congress has implemented patent
legislation in a variety of ways over the last 200 years, but the general
purpose remains unchanged: to promote scientific research and discovery
in furtherance of societal good.20 Patents grant inventors the exclusive
right over their inventions or discoveries for twenty years from the date on
which they file the applications that yield their patents. 21 In exchange for
this exclusivity, the patentee must make a written description of his work
publicly available.22

14. But see Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702
F. Supp. 2d 181, 220-38 (S.D.N.Y. 2010) (invalidating the patents under section 101 of
the U.S. Patent Act).
15. See infra Part II (describing the scope of 35 U.S.C. § 101 and its limitations).
16. See infra Part III (arguing that gene sequences are patentable when isolated,
and that the breast-cancer testing methods are valid because the steps are sufficiently
definite).
17. See infra Part IV (detailing how a research exemption could balance the tradeoffs of patent law for genetic research).
18. See infra Part V (concluding that gene patents are valid, and their prohibition
destroys research incentives).
19. U.S. CONST. art. I, § 8, cl. 8 (“To promote the Progress of Science and useful
Arts, by securing for limited Times to Authors and Inventors the exclusive Right to
their respective Writings and Discoveries.”).
20. E.g., 35 U.S.C.S. § 100 (LexisNexis 2010); see Diamond v. Chakrabarty, 447
U.S. 303, 308 (1980) (emphasizing that the exclusivity of patents is an incentive for
ingenuity).
21. E.g., § 154(a)(1), (2) (stating that a patent runs twenty years from the filing
date).
22. E.g., § 112; see also Rebecca S. Eisenberg, Patenting the Human Genome, 39
EMORY L.J. 721, 740-41 (1990) (arguing that the quid pro quo of the patent system
increases disclosure of findings, whereas researchers have less of an incentive to
otherwise publish their findings).
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B. United States Patent Act Section 101 & Subject-Matter Jurisprudence
Section 101 of the U.S. Patent Act sets the initial threshold for patentable
subject matter.23 It provides four categories of new and useful patentable
subject matter: machines, processes, manufactures, or compositions of
matter.24 A composition of matter includes combinations of two or more
substances.25 Meanwhile, courts carved out three exceptions to statutory
subject matter: laws of nature, abstract ideas, and physical phenomena.26
1. Laws of Nature
The laws of nature doctrine states that products of nature, exactly as
found in their natural state, constitute unpatentable subject matter.27 A
patentable composition must be the result of human ingenuity, such that it
cannot be repeated by nature.28 Courts, however, struggle in determining
whether laws of nature have been sufficiently altered into patentable
compositions.29
Courts initially determined that isolated, purified forms of products of
nature are patentable when they exhibit different qualities from their
naturally occurring forms.30 In Parke-Davis & Co. v. H.K. Mulford Co.,
Judge Learned Hand held that a purified form of adrenalin differed from its
natural form because it was removed from gland-tissue, purified from
associated salts, and it acquired new commercial and therapeutic uses.31 In
1970, the court in In re Bergstrom held that an isolated bodily compound
was patentable because it did not exist in nature as purified from tissues

23. See § 100; see also Bilski v. Kappos, 130 S. Ct. 3218, 3221 (2010) (adding that
inventions must also satisfy other statutory requirements).
24. See § 101 (implying that patents are further subject to standards of novelty,
non-obviousness, and a written description).
25. See Shell Dev. Co. v. Watson, 149 F. Supp. 279, 280 (D.D.C. 1957) (providing
that the term covers all composite articles as well)
26. See Bilski, 130 S. Ct. at 3225 (elaborating that these exceptions are not required
by statutory text).
27. See, e.g., Parker v. Flook, 437 U.S. 584, 593 (1978) (establishing that newly
discovered products of nature are not the discoveries section 101 was intended to
protect).
28. See, e.g., Diamond v. Chakrabarty, 447 U.S. 303, 313 (1980) (explaining that
patented compositions must result from human intervention).
29. Compare id. (validating a patent for a combination of bacterium that perform a
new function of breaking down crude oil), with Funk Bros. Seed Co. v. Kalo Inoculant
Co., 333 U.S. 127, 130 (1948) (invalidating a patent for a bacteria mixture that
performs its original function of inoculating plant seeds).
30. See, e.g., Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (S.D.N.Y.
1911) (noting that, at the time, no rule excluded unchanged extracted materials from
patent protection).
31. See id. (drawing the line between different compositions from common uses of
man, rather than from considerations of dialectic).
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and proteins.32
In 1980, the Supreme Court, in Diamond v. Chakrabarty, attempted to
qualify this standard, holding that nonnaturally occurring compositions, the
products of human ingenuity, are patentable subject matter.33 The Court
upheld the patentability of a combination of bacterium used to break down
crude oil, determining that they contained “markedly different”
characteristics from their natural forms and had potentially significant
utility.34 While the Court recognized the implications of its holding,
specifically for genetic research, its failure to precisely define “markedly
different” left courts unclear as to its application.35
Nevertheless, in 2001, the U.S. Patent and Trademark Office (PTO)
published the Utility Examination Guidelines, which addressed
patentability of isolated gene sequences. The PTO determined that isolated
gene sequences are chemical compositions and constitute patentable
subject matter, so long as such sequences meet other statutory
requirements. While the Guidelines are not binding on the courts, they are
given credence to the extent to which they do not conflict with statutory
subject matter under section 101.36
2. Process Claims
Although laws of nature are unpatentable, process claims that employ
laws of nature may still be patent-eligible.37 Section 100 of the U.S. Patent
Act defines processes as arts or methods, which include known processes,
machines, manufactures, or compositions of matter.38 Abstract principles,
which are considered fundamental truths, are unpatentable as they
effectively preempt entire fields of research and development.39 Courts
32. See 427 F.2d 1394, 1395-96, 1401-02 (C.C.P.A. 1970) (asserting that the
defendants did not merely discover prostaglandin).
33. See 447 U.S. at 309-10 (adding that the composition had a distinct character,
name, and use).
34. See id. at 310 (explaining that a new composition will differ in quality and use).
35. See, e.g., id. at 317 (suggesting that the legislature is the proper forum to weigh
competing interests of subject matter).
36. See In re Fisher, 421 F.3d 1365, 1372 (Fed. Cir. 2005) (referring to both the
Manual of Patent Examining Procedure and the Utility Examination Guidelines).
37. See Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948)
(holding that mixing existing strains of bacteria to inoculate plant seeds did not acquire
different uses or functional improvements).
38. See 35 U.S.C.S. § 100 (LexisNexis 2010) (providing definitions of several
terms used within the title); State St. Bank & Trust Co. v. Signature Fin. Grp., Inc., 149
F.3d 1368, 1373 (Fed. Cir. 1998) (describing a patentable process as one that creates a
“useful, concrete, and tangible result”).
39. See, e.g., Gottschalk v. Benson, 409 U.S. 63, 71-72 (1972) (implying that the
law does not recognize monopolies over abstract principles until they are applied to
new and useful ends).
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advise that process claims be confined within sufficiently definite bounds
to avoid issues of preemption.40
The Federal Circuit in In re Bilski devised the “machine-ortransformation” test, which delineated rigid guidelines under which to
evaluate process claims.41 Pursuant to this test, a process is patent-eligible
if (1) it is linked to a machine or other apparatus, or (2) it includes a
transformative step, changing an article into a different state.42 In
Prometheus Laboratories, Inc. v. Mayo Collaborative Services, the Federal
Circuit applied the machine-or-transformation test to a process of medical
diagnostic testing that involved identifying levels of a metabolite used to
treat gastrointestinal disorders.43 The method passed the machine-ortransformation test because the steps of administering the drug and
determining metabolite levels were transformative in that they were central
to the entire process and could not be done by mere inspection.44
In Bilski v. Kappos, the Supreme Court rejected the machine-ortransformation test as the exclusive or exhaustive test for process claims.45
The Court reasoned that the test is inflexible and contradicts the meaning of
the word “process” in section 100, because the statute does not contemplate
tying processes to machines or transformative steps.46 While the machineor-transformation test is still valid, it now serves as only a clue to
patentability for process claims, rather than as the exclusive or exhaustive
test.47
C. Association for Molecular Pathology v. United States Patent &
Trademark Office
Myriad Genetics and the University of Utah Research Foundation
(collectively “Myriad”) hold patents on breast cancer susceptibility gene

40. See id. at 69 (explaining that a chemical process that transforms rubber did not
monopolize an entire field because the process was applied to a specific use).
41. E.g., 545 F.3d 943, 964-66 (Fed. Cir. 2008) (invalidating a patent for a business
method of hedging risk).
42. See id. at 954, 961-62 (explaining that the transformation must be central to the
entire process to be patent-eligible).
43. See 581 F.3d 1336, 1343 (Fed. Cir. 2009) (observing that doctors use the
metabolite levels to alter dosages).
44. See id. at 1346 (adjudicating that the administration of metabolites caused
transformative physical changes in the body).
45. See 130 S. Ct. 3218, 3220 (2010) (decrying the machine-or-transformation
test’s exclusive use, but failing to provide new guidelines), rev’g In re Bilski, 545 F.3d
943 (Fed. Cir. 2008).
46. See Bilski, 130 S. Ct. at 3220 (recognizing that the ordinary meaning of the
word “process” does not mean machine or transformation).
47. See id. (invalidating a business-method patent on hedging because it patented
an abstract idea).

Published by Digital Commons @ American University Washington College of Law, 2011

7

BOUTROS 4/5/11

9/1/2011 6:25 PM

Journal of Gender, Social Policy & the Law, Vol. 19, Iss. 3 [2011], Art. 10

1016

JOURNAL OF GENDER, SOCIAL POLICY & THE LAW

[Vol. 19:3

sequences and the cancer susceptibility tests that utilize those sequences.48
Plaintiff Association for Molecular Pathology, along with several other
research institutions and breast- and ovarian-cancer patients, filed a lawsuit
against the U.S. Patent and Trademark Office and Myriad Genetics in the
Southern District of New York to declare Myriad’s patents invalid in light
of: (1) section 101 of the U.S. Patent Act, (2) Article 1, section 8, clause 8
of the U.S. Constitution, and (3) the First and Fourteenth Amendments of
the U.S. Constitution.49 At the heart of their claims, Plaintiffs asserted that
the gene and testing-method patents represent laws of nature and abstract
principles, respectively, and thus fall under the exceptions to statutory
subject matter.50 The Southern District of New York granted the motion
and invalidated Myriad Genetics’ patents.51
1. The Patents-In-Suit
Myriad’s patents encompass two types of claims: composition claims
and method claims.52 The composition claims are for isolated, purified
BRCA1 and BRCA2 gene sequences.53 The method claims, which relate to
Myriad’s Comprehensive BRACAnalysis Rearrangement Test and its 2006
BRACAnalysis Rearrangement Test (“BART”), cover the process of
isolating the patient’s DNA, inserting an altered BRCA gene into the host
cell, and “analyzing” and “comparing” the BRCA1 and BRCA2 sequences
against human samples for the growth of cancer therapeutics.54
2. Opinion
The Southern District of New York held that gene sequences are laws of
nature and, thus, unpatentable subject matter.55 The court reasoned that the
48. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181, 184 (S.D.N.Y. 2010) (referring to fifteen claims within Myriad’s seven
patents).
49. See, e.g., id. (refusing to address the Constitutional claims after invalidating the
gene patents as laws of nature).
50. See generally id. (focusing primarily on the claims brought under section 101
of the United States Patent Act).
51. See id. at 186 (denying defendants’ cross-motion for summary judgment).
52. See id. at 211 n.25 (acknowledging that the patents were approved pursuant to
the Patent and Trademark Office’s policy that allows for patents on “isolated and
purified” DNA).
53. See, e.g., U.S. Patent No. 5,693,473 (filed June 7, 1995) (issued Dec. 2, 1997);
see also Ass’n for Molecular Pathology, 702 F. Supp. 2d at 231 (noting this gene
sequences corresponds with other DNA sequences containing the same nucleotide
sequence).
54. See, e.g., ’473 Patent; see also Ass’n for Molecular Pathology, 702 F. Supp. 2d
at 213 (explaining that each of the method patents are similarly structured, describing
methods of comparing human samples with the BRCA1 and BRCA2 sequences).
55. See Ass’n for Molecular Pathology, 702 F. Supp. 2d at 185 (dismissing
Myriad’s claims that “laws” and “products” of nature are distinguishable).
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isolated sequences did not contain markedly different characteristics from
their naturally-occurring forms and, as such, were an embodiment of their
original characteristics.56 The court stated that DNA’s composition is
unique in nature and refused to treat it similar to chemical compositions,
whereby isolation from associated components turns chemicals into
patentable compositions.57
Moreover, the court held that Myriad’s method claims were invalid
because, pursuant to the now-denigrated machine-or-transformation test,
the method does not involve transformative steps.58 The court stated that
although Myriad’s test requires isolating patient tissue samples, this is a
preparatory step, rather than one that is central and transformative.59 The
court added that Myriad’s BRCA testing methods represented abstract
processes of comparison and analysis, thus falling under the judicially
created exceptions to patentable subject matter.60
III. ANALYSIS
A. The Southern District of New York Erred in Invalidating the BRCA1 and
BRCA2 Patents Because Isolated Gene Sequences are Compositions of
Matter Under Section 101 and Do Not Fall Within the Laws of Nature
Exception.
The Southern District of New York, in its 152-page, policy-driven
opinion, arbitrarily dismissed basic tenets of patent law jurisprudence.
Patent law is designed to provide rewards for new inventions or discoveries
that are products of human ingenuity.61 Both the framers of the
Constitution and Congress intended for the patentability of newly
discovered compositions.62 The Patent Clause of the Constitution states
56. See id. at 228 (citing Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980))
(establishing that the fundamental characteristic of DNA as “physical carriers of
information” has been preserved in the isolated gene sequence).
57. See id. (distinguishing DNA from other chemical compositions because DNA
encodes information about construction of the human body, not its molecular
structure).
58. See id. at 235 (rejecting Myriad’s claim that the BRCA tests require
transformation of tissue and blood samples).
59. See id. at 234, 236 (citing In re Grams, 888 F.2d 835, 840 (1989)) (determining
that the test is nothing more than data-gathering and analysis).
60. See id. at 234 (citing In re Bilski, 545 F.3d 943, 953 (Fed. Cir. 2008))
(reasoning that the plain and ordinary meaning of the terms relates only to abstract
mental processes and not transformative ones).
61. See Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980) (explaining that
products become patentable when their functions, uses, or transformations into new
compositions are products of human labor).
62. See Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001)
(expounding that the language of the Constitution and section 101 intentionally include
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that inventors shall have an exclusive right over their discoveries.63 When
Congress later enacted the U.S. Patent Act, it stated that one may receive a
patent for any process, machine, composition of matter, or manufacture that
he invents or discovers.64 The broad language of these texts evinces that
both the framers and Congress left the door open for inclusion of
discoveries as patentable subject matter.65 While new compositions are not
patentable in their natural states, isolated, purified compositions have since
been recognized as patentable when they exhibit nonnaturally occurring
uses and qualities.66 Myriad should, thus, be rewarded for its first-in-time
discovery and isolation of the BRCA1 and BRCA2 gene sequences.
1. The Isolated, Purified BRCA Gene Sequences Are Patentable Subject
Matter Because They Have Been Removed from All Associated Content and
Are, Thus, Different from Their Naturally Occurring Forms.
Myriad’s BRCA1 and BRCA2 gene sequences are patentable subject
matter because the DNA molecules have been isolated and purified from
associated components on the chromosome. Courts have recognized
chemical compositions as patentable subject matter when they have been
isolated and purified from associated components in their natural states.67
In Parke-Davis & Co. v. H.K. Mulford Co., the court held that isolated
adrenalin was characteristically different because it was purified from its
salt-based, naturally-occurring state.68 In In re Bergstrom, the Court of
Customs and Patent Appeals upheld a patent on a bodily composition
because the patented form was isolated and removed from associated
tissues and proteins.69
Similarly, a purified, isolated gene sequence is distinguishable from its
discoveries).
63. See U.S. CONST. art. I, § 8, cl. 8 (proclaiming authors and inventors should
have the exclusive rights over their writings and discoveries); Utility Examination
Guidelines, 66 Fed. Reg. at 1093 (explaining that the discovery of a gene may be the
basis for patentable subject matter).
64. See 35 U.S.C.S. § 101 (LexisNexis 2010) (stating one may obtain a patent
when he invents or discovers a new or useful composition); Utility Examination
Guidelines, 66 Fed. Reg. at 1093 (noting that a gene patent is valid so long as it also
satisfies the utility requirement).
65. See Utility Examination Guidelines, 66 Fed. Reg. at 1093 (contending that
discoveries with specific, substantial uses were meant to be patented).
66. See In re Bergstrom, 427 F.2d 1394, 1398 (C.C.P.A. 1970) (articulating that
purified compositions are considered different if they exhibit new properties).
67. See, e.g., Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (S.D.N.Y.
1918); see also Bergstrom, 427 F.2d at 1398.
68. See id. at 103 (articulating that the practical differences, not the scholastic
distinctions, between the pure and impure form support upholding the patent on
adrenalin).
69. See Bergstrom, 427 F.2d at 1398 (contending that a separate factor to consider
is the composition’s usefulness in lowering blood pressure).
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impure form on a chromosome.70 DNA has both structural and functional
properties: (1) it is structurally a chemical composition, and (2) it serves a
biological function of encoding proteins.71 While the court acknowledged
these functional properties of DNA, it refused to treat gene sequences as
chemical compositions and to accept the notion that the isolation of the
sequence’s chemical structure creates a patentable composition.72
Myriad’s patents claim the isolated, chemical structure of the BRCA
sequences.73 The BRCA1 and BRCA2 gene sequences, as chemical
compositions, fall within the scope of section 101 as a composition of
matter because these DNA molecules are a combination of nucleotide
sequences.74 While these compositions are not patentable compositions
when left on their respective chromosomes, they, like other chemical
compositions, constitute patentable subject matter when removed and
purified from their natural states.75
The BRCA1 and BRCA2 sequences, when found on their respective
chromosomes, are products of nature, and as such, their primary purpose is
to carry information within the full gene sequence.76 Their existence in that
natural state on the chromosomes is the product of biological functions, and
is thus, nature’s work.77 Once researchers isolate and purify a gene
sequence from its original state, the resulting product is a new manufacture
or composition of matter.78 The sequence has been isolated from any
70. See Utility Examination Guidelines, 66 Fed. Reg. at 1093 (explaining that the
isolated compound described by the DNA sequence constitutes patentable subject
matter); cf. Bergstrom, 427 F.2d at 1401-02 (clarifying that a purified chemical
compound, known as prostaglandin, is patentable because it cannot be found in purified
form in the body).
71. See, e.g., Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office,
702 F. Supp. 2d 181, 228 (S.D.N.Y. 2010) (describing the testimony by Myriad’s
expert that DNA is multifunctional).
72. See, e.g., id. at 231-32 (stating that DNA retains its property of encoding
proteins and carrying information).
73. But see id. at 229 (asserting that DNA carries a unique function and that the
functions of other chemical compounds are not comparable).
74. Cf. Shell Dev. Co. v. Watson, 149 F. Supp. 279, 280 (D.D.C. 1957) (defining a
composition of matter as a combination of two or more substances, including call
composite articles, regardless of whether they are gases, fluids, powders, or solids).
75. See Utility Examination Guidelines, 66 Fed. Reg. at 1093 (contending that
Congress intended for patents on isolated chemical structures).
76. See, e.g., Ass’n for Molecular Pathology, 702 F. Supp. 2d at 228-29 (describing
the biological function of DNA for coding proteins and directing the synthesis bodily
molecules).
77. Cf. Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980) (reasoning that nonnaturally occurring compositions are patentable because they require human ingenuity);
Utility Examination Guidelines, 66 Fed. Reg. at 1093 (proclaiming that isolated DNA
is non-naturally occurring).
78. See In re Bergstrom, 427 F.2d 1394, 1401 (C.C.P.A. 1970) (implying that
purified prostaglandin is a new composition because it has been removed from all
associated components in its natural form in the body).
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adjacent, or even overlapping, gene sequences, and it has been purified of
any associated components.79 This purified sequence cannot be repeated
by or found in nature.80 The isolated form of the BRCA1 and BRCA2 gene
sequences is solely the result of human ingenuity, experimentation, and
manipulation.81
Furthermore, PTO practice and guidelines similarly recognize an isolated
gene sequence as patentable subject matter.82 The PTO, in its Utility
Examination Guidelines, stated that the broad scope of section 101 supports
its practice that DNA sequences are patentable once isolated and purified
from their natural states.83 The Guidelines further clarify that the sequence
data, or just the descriptive information of the sequence, is not patentable;
the Guidelines only support patenting an isolated DNA molecule.84 Thus,
under PTO practice and guidelines, Myriad’s isolated gene sequence,
which patents an isolated DNA molecule, is patentable subject matter.85
Because isolated gene sequences constitute patentable subject matter, the
Southern District of New York erroneously invalidated Myriad’s gene
patents.
2. The Isolated BRCA Gene Sequences Are Patentable Because Their
Acquisition of a New Utility for Cancer Testing Constitutes a Different
Characteristic That Is Solely the Result of Human Manipulation.
The Southern District of New York improperly applied the Chakrabarty
standard not only by holding that isolated gene sequences are not markedly
different, but also by failing to recognize that an isolated gene sequence
acquires a significant new utility.86 The Chakrabarty Court validated a
79. See, e.g., U.S. Patent No. 5,693,473 (filed June 7, 1995) (issued Dec. 2, 1997)
(defining an isolated sequence as one that is separated from other cellular components).
80. See Chakrabarty, 447 U.S. at 313 (elaborating that the new bacterium was a
human-made invention because it required the patentee’s ingenuity).
81. See id. (explaining that Congress recognized human ingenuity as the difference
between products of nature and patentable inventions).
82. See Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001)
(responding to public comments and concerns over the patentability of gene
sequences); cf. In re Fisher, 421 F.3d 1365, 1372 (Fed. Cir. 2005) (recognizing the
Utility Examination Guidelines to the extent that they do not conflict with patent
statutes).
83. See Utility Examination Guidelines, 66 Fed. Reg. at 1093 (citing Diamond v.
Chakrabarty, 447 U.S. 303, 309 (1980)) (explaining that Congress intended to patent
anything under the sun, which includes non-naturally occurring gene sequences).
84. See id. (reasoning that the gene sequence data, which only includes information
on the strings of letters and pairs, is nonfunctional descriptive information and is
unpatentable).
85. See, e.g., U.S. Patent No. 5,693,473 (filed June 7, 1995) (issued Dec. 2, 1997)
(claiming an invention relating to methods and materials used to isolate and detect
BRCA1).
86. See Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980) (distinguishing Funk
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patent on a bacterium combination, clarifying that it not only had markedly
different characteristics but also a potentially significant utility to break
down crude oil.87 The Supreme Court envisioned this standard for
patentability encompassing more than just a change in characteristics.88 It
includes the acquisition of different uses beyond those originally produced
by nature.89 In Parke-Davis, the court also emphasized that isolated,
purified adrenalin was effectively different and, therefore, patentable
because it gained commercial and therapeutic new uses for blood pressure
treatment.90
Likewise, a gene sequence becomes commercially and therapeutically
new upon isolation and purification.91 The isolated gene sequences possess
significant utility as means to a new end: markers for the breast cancer
gene.92 The BRCA sequences then serve as the guideposts against which to
test for predispositions to breast or ovarian cancer.93 The patentees utilize
the BRCA1 and BRCA2 gene sequences in their breast cancer
susceptibility test to perform this guidepost function.94 These isolated,
purified gene sequences no longer serve the ends nature originally
provided, but rather serve a significant new utility through the patentees’
manipulation.95 The Southern District of New York, thus, erred in
Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 131 (1948)) (deciding that the
patentee genetically manipulated the bacterium to acquire a significant new utility).
But see Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181, 232 (S.D.N.Y. 2010) (likening Myriad’s patent claim to the bacterial
mixture in Funk Bros.).
87. See Chakrabarty, 447 U.S. at 305 (emphasizing the bacterium’s value for
treatment of oil spills).
88. See id. at 310 (requiring a showing that the discovery yields both a new
characteristic and a new utility in order to be patentable); see also Hoffman, supra note
6, at 1018 (speculating that isolating and purifying a gene sequence sufficiently applies
a “law of a nature to a new and useful end”).
89. See Chakrabarty, 447 U.S. at 313 (countering the argument that Congress
intended to distinguish between living and inanimate things and instead suggesting that
Congress intended to distinguish between “products of nature” and “human-made
inventions”).
90. See 189 F. 95, 103 (S.D.N.Y. 1911) (holding that once the patentee extracted
the compound from inorganic matter, it was changed from an inert substance to a
potentially useful one).
91. Cf. id. (insisting that practical differences between an isolated composition and
its natural form serve as keys to determining patentability); Merck & Co., Inc. v. Olin
Mathieson Chem. Corp., 253 F.2d 156, 163-64 (4th Cir. 1958) (explaining that a
purified composition with new utility is an invention because, without isolation, it
would not have such a use).
92. Cf. Merck, 253 F.2d at 164 (upholding a patent for vitamin B(12) in purified
form that had potential medical uses).
93. See, e.g., U.S. Patent No. 5,693,473 (filed Jun. 7, 1995) (issued Dec. 2, 1997)
(claiming diagnosis of predisposition to breast and ovarian cancer as a utility of the
isolated gene).
94. See id.
95. Cf. Chakrabarty, 447 U.S. at 310 (explaining that compositions are patentable
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invalidating Myriad’s gene patents by ignoring the marked differences in
the isolated sequences.
B. The Southern District of New York Erred in Invalidating Myriad’s
Method Claims Because the Test Involves Transformative Steps and the
Claims Do Not Seek to Patent Abstract Mental Processes.
1. Myriad’s Method Claims Are Patentable Under the Machine-orTransformation Test Because the Process of Isolating Patient Tissue
Samples Is a Central, Transformative Step.
The Southern District of New York improperly dismissed Myriad’s
method claims under the machine-or-transformation test by failing to
consider the claim as a whole and holding that the methods did not contain
transformative steps.96 Although the court was bound to apply the
machine-or-transformation test at the time of its decision, the court
incorrectly applied the test by discarding the methods’ central processes as
irrelevant.97
The Federal Circuit in Prometheus Laboratories, Inc. v. Mayo
Collaborative Services stated that a process of determining metabolite
levels in a body is considered a transformative step.98 The metabolite
determination was transformative because it was central to the treatment
process, and the determination could not be done by mere inspection of the
patients.99 Similarly, Myriad’s process claim, whereby it must compare
and analyze DNA, is transformative.100 Myriad described the method as
transforming patient tissue and blood samples to isolate the patient’s

when they cannot be repeated by nature without human intervention).
96. See, e.g., Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office,
702 F. Supp. 2d 181, 233 (S.D.N.Y. 2010) (contending that steps of comparison and
analysis were the underlying bases of the method claims).
97. See In re Bilski, 545 F.3d 943, 961-62 (Fed. Cir. 2008) (ruling that the
machine-or-transformation test is the exclusive test for process claims), remanded sub
nom. Bilski v. Kappos, No. 08-964, 2010 U.S. LEXIS 5521, at *16-18 (Jun. 28, 2010)
(rejecting the machine-or-transformation test because it creates too much uncertainty in
the Information Age). But see Ass’n for Molecular Pathology, 702 F. Supp. 2d at 23435 (reasoning that isolation of tissue indicates the source of the tissue, but is not central
to the method).
98. E.g., 581 F.3d 1336, 1346 (Fed. Cir. 2009) (explaining that the human body
and the drug’s metabolites underwent physical and chemical changes), vacated, No. 09490, 2010 U.S. LEXIS (Jun. 29, 2010) (remanding the case for reconsideration in light
of Bilski v. Kappos, No. 08-964, 2010 U.S. LEXIS 5521 (Jun. 28, 2010)).
99. See Prometheus, 581 F.3d at 1347 (holding that a method for measuring
metabolite levels survived the machine-or-transformation test).
100. But see Ass’n for Molecular Pathology, 702 F. Supp. 2d at 234 n.56 (limiting
its interpretation to DNA sequences, thereby ignoring similar claims related to RNA
and cDNA).
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DNA.101 The court, however, explained that the process of isolation could
not be attributed to a transformation because the isolation merely describes
where the DNA came from.102 The court further stated that Myriad’s entire
claim was directed to abstract mental processes of comparison and
analysis.103
The court should not have dismissed the isolation of patient tissue
samples as lacking transformation because the process of isolating the
patient tissue and DNA sample is central to the diagnostic testing.104 Just
as the metabolite levels in Prometheus could not be tested by mere
inspection, testing the patient’s DNA requires more than inspection.105
Although isolating the patient samples is the first step of the process, it is
more than just a preparatory step.106 The process involves taking the
patient’s tissue and blood samples, manipulating the samples to isolate the
corresponding DNA molecules, inserting an altered BRCA1 gene into the
cell, and testing for a cancerous predisposition.107 Isolating the DNA
molecules from the patient samples is central to the overall process because
researchers cannot successfully accomplish testing without this initial,
critical step.108
The court further limited the claim’s terms and stated that the isolation
process in the method claim cannot be differentiated from the isolated
DNA in the composition claims.109 While the same term is used, each
claim is distinct. The composition claim was entirely directed toward
isolated, purified BRCA1 and BRCA2 gene sequences.110 The method
101. See id. (reiterating Myriad’s argument that comparison and analysis are central
to the transformation).
102. E.g., id. at 236 (citation omitted) (decrying that Myriad attempted to import
claim limitations).
103. See id. at 237 (alleging the claims would fail the test even if the court
considered the isolation process transformative).
104. Cf. Prometheus, 581 F.3d at 1347 (explaining that a step required to determine
levels is not merely a data-gathering step because it is part of the treatment).
105. See id. (indicating that some form of manipulation is required to extract
metabolite samples and determine the levels within the body).
106. Cf. id. (holding that a diagnostic test that incorporates a step of determining
metabolite levels is central to a process because it is necessary for therapeutic
treatment).
107. See Ass’n for Molecular Pathology, 702 F. Supp. 2d at 233 (describing
Myriad’s argument that isolating the patient’s DNA molecules is a physically
transformative step because the DNA cannot be isolated without the transformation of
the tissue samples).
108. But see id. at 235 (contending that the purpose was to detect germline
alterations, while the actual method claimed was one of comparison and analysis).
109. Compare Diamond v. Chakrabarty, 447 U.S. 303, 308 (1980) (implying that
courts should not violate principles of patent interpretation by reading limitations into
the patent’s scope), with Ass’n for Molecular Pathology, 702 F. Supp. 2d at 236
(alleging that Myriad seeks to change the scope of the claims).
110. See Ass’n for Molecular Pathology, 702 F. Supp. 2d at 203 (describing two
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incorporates a process of isolation that is central to the researchers’ ability
to compare the patient’s DNA to the BRCA1 and BRCA2 gene sequences
encompassed in the composition claims.111 Thus, the Southern District of
New York incorrectly invalidated Myriad’s method claim.
2. Myriad’s Method Claims Are Patentable in the Wake of Bilski Because
They Are Confined Within Sufficiently Definite Bounds.
Pursuant to the Supreme Court’s recent decision in Bilski v. Kappos, the
machine-or-transformation test should not be used exclusively to evaluate
the validity of method claims.112 The machine-or-transformation test now
serves merely as a clue to patentability for method claims.113 The Court
reasoned that the test proves too narrow and rigid, and its use as an
exhaustive test would preclude patents for innumerable inventions that
would otherwise be patentable.114 In the wake of Bilski, courts should
consider the patent claims as a whole without confining their
interpretations to the inflexible machine-or-transformation test.115
Courts should determine whether the method either covers an abstract
principle or is directed toward some other process that otherwise
constitutes statutory subject matter.116 An abstract principle is considered a
fundamental truth, over which no one can claim an exclusive right.117
Alternatively, a process is a manner of treating materials to produce a given
result, and the tools used in producing such a result are considered to be of

separate patents-in-suit: claims for isolated gene sequences and claims for
predisposition tests applying the sequences).
111. See, e.g., U.S. Patent No. 5,709,999 (filed June 7, 1995) (issued Jan. 20, 1998)
(detailing the process of detecting germline alterations as incorporating the obtainment
of a human sample and detecting the alteration by amplifying all or part of the BRCA1
gene).
112. See 130 S. Ct. 3218, 3226 (2010) (observing that use of the machine-ortransformation test would read a limitation into section 101).
113. E.g., id. (citing Corley v. United States, 129 S. Ct. 1558 (2009)) (noting that the
machine-or-transformation test would also render section 273 of the U.S. Patent Act
superfluous, which allows for infringement claims for methods in patents).
114. See, e.g., id. (emphasizing that exclusive use of the machine-or-transformation
test precludes patentability of diagnostic medical techniques and other unforeseen
inventions).
115. See, e.g., id. See generally King Pharm. v. Eon Labs, Inc., 616 F.3d 1267 (Fed.
Cir. 2010) (applying the Supreme Court’s Bilski holding, although disagreeing with the
rationale behind disallowing the machine-or-transformation tests exclusive use for
process claims).
116. See generally Diamond v. Diehr, 450 U.S. 175, 187 (1981) (determining that
when an abstract principle is applied to a specific, patentable process, the patent does
not preempt a field and is valid).
117. E.g., Gottschalk v. Benson, 409 U.S. 63, 67 (1972) (quoting Le Roy v. Tatham,
55 U.S. 156, 175 (1853)) (holding that a mathematical algorithm is a fundamental truth,
and thus, an unpatentable abstract principle).
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secondary consequence.118
While an abstract principle is itself
unpatentable, application of an abstract principle to a process claim may
still constitute patentable subject matter.119 The key to patentability is
whether the abstract principle is applied to a specific process or used to
refine such a process.120 If an abstract principle is applied to a patentable
method, the patent may still be valid if it seeks to patent the process itself
and not the applied abstract principle.121 A process claim that is too general
may be unpatentable if it wholly preempts an entire field.122 Courts have,
thus, cautioned that process claims must be confined to sufficiently definite
bounds.123
Illustratively, a process claim seeking to patent a mathematical formula,
without application to a specific invention or use, is unpatentable because it
effectively patents the algorithm itself, thus limiting its use in other
formulas.124 Meanwhile, the use of magnetism to transmit sounds,
specifically applied to a telephone, is patentable because it does not seek to
patent electricity, but rather an electrical current used in a specified, narrow
circumstance.125
Under this broader analysis, Myriad’s process claims are even more
clearly patentable. Myriad’s BART test includes three basic steps for
researchers: (1) isolate the patient’s blood and tissue sample; (2) insert an
altered BRCA1 gene, which simulates cancerous cells, into the host cell to
test for the presence or absence of cancer therapeutics; and (3) compare and
analyze growth rates in the host cell for the presence of a cancer
118. See, e.g., Cochrane v. Deener, 94 U.S. 780, 787-88 (1877) (providing that a
process of manufacturing flour is patentable because it reduced the grain to a different
state).
119. See In re Grams, 888 F.2d 835, 840 (Fed. Cir. 1989) (holding that a test for
diagnosing abnormalities is not patentable because the steps involving a mathematical
algorithm did not have specific applications and were only data-gathering steps).
120. See id. at 838 (citing In re Walter, 618 F.2d 758 (C.C.P.A. 1980)) (ruling that a
mathematical algorithm must either be specifically applied to define structural
relationships of a claim or to refine or limit patentable claim steps).
121. Compare Diehr, 450 U.S. at 187 (upholding a patent for an algorithm applied
to a process for curing synthetic rubber), with Gottschalk, 409 U.S. at 67, 71-72
(invalidating a patent for a mathematical formula because it could only be applied in
connection with computers, which were not the object of the patent).
122. See Parker v. Flook, 437 U.S. 584, 589-90 (1978) (explaining that a process
using a mathematical algorithm was unpatentable because there was no invention, and
the patent would wholly preempt the use of the algorithm in other equations).
123. See Gottschalk, 409 U.S. at 71-72 (describing how a process utilizing a
mathematical formula could not be patented because the claim was so broad as to cover
both known and unknown uses of the conversion formula).
124. See id. at 68 (invalidating a patent for a process of converting binary-coded
decimal numerals into binary numbers because it was overly broad and encompassed
an entire algorithm).
125. See id. at 68-69 (stating that the patent associated with Bell’s telephone was
valid because it was not for all telephonic use of electricity).
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therapeutic, whereby a slower growth rate is indicative of its presence.126
The steps involve treating materials in order to achieve a deliberate result: a
triggered response by the host cell.127 The patient’s blood and tissue
sample is isolated, and the BRCA gene is inserted to test growth rates for
cancer therapeutics, thereby specifically determining whether a patient is
susceptible to breast or ovarian cancer.128 By applying the machine-ortransformation test as a clue to patentability, the testing method, which
includes processes of isolating the patient’s tissue samples and inserting a
gene sequence to change growth rates, involves transformative steps.129
However, the court reasoned that Myriad’s method claim was not
patentable because the third step, which describes a process of comparing
growth rates, is an abstract mental process.130
Myriad’s process claims do not seek to patent abstract mental processes
simply because they incorporate steps of comparison and analysis.131
Myriad’s claims, taken as a whole, are confined to sufficiently definite
bounds, such that they will not preempt the fields of genetics or medical
diagnostic testing.132 The method claims primarily patent the process of
isolating the patient’s tissue sample, inserting the cancer-mimicking gene,
and testing growth rates.133 These abstract principles are applied in
Myriad’s claims to growth-rate tests after a BRCA1 gene sequence is
inserted into the host cell.134 Myriad simply used analysis and comparison
as a tool to achieve the result of breast and ovarian cancer susceptibility
testing.135 Myriad refined its use of abstract processes of comparison and

126. But see Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702
F. Supp. 2d 181, 236 (S.D.N.Y. 2010) (dismissing Myriad’s claims and stating that the
isolation of the patient samples is not transformative and is, instead, merely datagathering).
127. Cf. Cochrane v. Deener, 94 U.S. 780, 787-88 (1877) (defining a process as a
method of treating materials towards the production of a given result).
128. See, e.g., U.S. Patent No. 5,709,999 (filed June 7, 1995) (issued Jan. 20, 1998)
(specifying the process under which researchers test for breast cancer predispositions).
129. See, e.g., Bilski v. Kappos, 130 S. Ct. 3218, 3226 (2010) (cautioning that the
machine-or-transformation test should not be used exclusively).
130. See Ass’n for Molecular Pathology, 702 F. Supp. 2d at 237 (asserting Myriad’s
description of comparing growth rates is an attempt to patent the scientific method).
131. Cf. In re Grams, 888 F.2d 835, 840 (Fed. Cir. 1989) (providing that an abstract
process may be used to refine other patentable processes).
132. See Gottschalk v. Benson, 409 U.S. 63, 71-72 (1972) (avoiding the issue of
whether the Court is the proper forum to extend the application of patent law to
mathematical algorithms because it does not have the power to conduct hearings and
canvass opposing views).
133. See, e.g., King Pharm. v. Eon Labs, Inc., 616 F.3d 1267, 1277 (Fed. Cir. 2010)
(reaffirming the idea that patents must be looked at in their entirety, rather than by
isolating each claim and assessing them separately).
134. See Ass’n for Molecular Pathology, 702 F. Supp. 2d at 237 (conceding that the
steps taken prior to comparing the growth rates of cells may be transformative).
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analysis to its otherwise patentable processes.136
The process claim explicitly describes a series of specific steps that
allow researchers and doctors to determine whether a patient is genetically
predisposed to breast or ovarian cancer.137 The process claims do not
purport to preempt abstract mental processes of comparison and analysis.138
Thus, in the wake of Bilski v. Kappos, Myriad’s process claims for BRCA1
and BRCA2 cancer predisposition testing are patentable.139 Accordingly,
under the tests established by the Supreme Court in Chakrabarty and
Bilski, the Southern District of New York erred in its decision as to both the
composition and method claims as a matter of law.140
IV. POLICY IMPLICATIONS AND RECOMMENDATIONS
Sound policy reasoning further supports the patentability of Myriad’s
claims. Congress enacted the U.S. Patent Act to promote the progress of
science and society, thus leaving open the scope of patentable subject
matter.141 While patents on gene sequences could arguably inhibit
scientific research, their prohibitions effectively serve an equal or greater
harm to society.142
Genetics research is time- and cost-intensive.143 Research institutions
135. Cf. Cochrane v. Deener, 94 U.S. 780, 787-88 (1877) (holding that the tools
used to manufacture grain are only secondary to the actual manufacture the patentee
sought to patent).
136. Cf. Grams, 888 F.2d at 840 (determining that the test of patentability should be
read as requiring that a principle be applied in any manner to physical process steps).
137. See, e.g., U.S. Patent No. 5,693,473 (filed June 7, 1995) (issued Dec. 2, 1997)
(describing the process of detecting germline alterations using the BRCA1 gene).
138. Cf. Diamond v. Diehr, 450 U.S. 175, 187 (1981) (reasoning that the application
of a mathematical algorithm to a process of curing synthetic rubber only claims the
exclusive right to use that equation for the rubber curing process).
139. See 130 S. Ct. 3218, 3231 (2010) (asserting that the test is too rigid for
exclusive use).
140. See Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980) (setting the markedly
different standard); In re Bilski, 545 F.3d 943, 953 (Fed. Cir. 2008) (applying the
machine-or-transformation test exclusively), remanded sub nom. In re Bilski, 130 S.
Ct. 3218, 3226 (condemning the machine-or-transformation test’s exclusive use for
method claims). But see Ass’n for Molecular Pathology v. U.S. Patent & Trademark
Office, 702 F. Supp. 2d 181, 185 (S.D.N.Y. 2010) (explaining that DNA, even in its
isolated form, is the embodiment of biological information).
141. See Chakrabarty, 447 U.S. at 308-09 (articulating that the scope of
patentability is open to “anything under the sun”). But see Bilski, 130 S. Ct. at 3229
(setting a high bar for patentability to prevent slowing creativity).
142. See Chakrabarty, 447 U.S. at 317 (suggesting genetic research is dependent on
rewards and incentives); see also Alex Osterlind, Staking a Claim on the Building
Blocks of Life: Human Genetic Material within the United States Patent System, 75
MO. L. REV. 617, 619 (2010) (describing the difficulties in reconciling the competing
interests of gene patents).
143. See Hoffman, supra note 6, at 996 (discussing the benefits obtained by the
public from patenting inventions that might not have otherwise been produced because

Published by Digital Commons @ American University Washington College of Law, 2011

19

BOUTROS 4/5/11

9/1/2011 6:25 PM

Journal of Gender, Social Policy & the Law, Vol. 19, Iss. 3 [2011], Art. 10

1028

JOURNAL OF GENDER, SOCIAL POLICY & THE LAW

[Vol. 19:3

may be unwilling, or even unable, to engage in such beneficial research
without the necessary incentives.144 Patents provide two interconnected,
reward-based incentives: (1) the patent itself rewards patentees for their
labor through a grant of exclusivity over their inventions or discoveries,
and (2) patents provide the means necessary for researchers to receive the
monetary backing for the continuation of their work.145 A patentee may be
less likely to receive funding for his research without the necessary endresult of exclusivity over his invention or discovery.146
Myriad, like the other institutions that raced to sequence the breast
cancer susceptibility gene, worked tirelessly knowing that if it could
sequence the gene first, it would be rewarded with a patent.147 The
prospect of the patent then made it possible for Myriad to receive funding
for its efforts.148 This funding also exists because Myriad, as the institution
with control of the gene sequence and corresponding test, can balance the
costs of research with the profits received from exclusively conducting the
BART test.149 Without these incentives, Myriad and other researchers may
not have sequenced the gene as expediently, or at all.150
Nevertheless, opponents argue that patents hinder research because they
prohibit other institutions from using the gene sequence for inquisitive
research.151 For the BRCA1 and BRCA2 sequences, patient samples must
be sent to Myriad’s facilities for testing at a high cost.152 Patients are then
of high production costs).
144. E.g., Wetkowski, supra note 10, at 182 (acknowledging the potential for the
United States to fall behind other countries in the field of genetic research if scientists
cannot obtain patents and, consequently, funding for research).
145. See Nowierski, supra note 12, at 506 (adding that patents are an incentive for
public disclosure); see also Wetkowski, supra note 10, at 182 (asserting that
researchers will not be willing to engage in research and development without patents).
146. See Michael D. Davis, The Patenting of Products of Nature, 21 RUTGERS
COMPUTER & TECH. L.J. 293, 346 (1995) (noting that the ability to receive commercial
rewards is the foundation of all of patent law and not just exclusive to biotechnology
patents).
147. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181, 210 (S.D.N.Y. 2010) (describing the competition from institutions
receiving federal grants).
148. See, e.g., id. at 201 (referring to the total $122 million in funding that Myriad
received during a three-year period).
149. See, e.g., id. at 203 (noting that Myriad’s 2008 costs of providing the test was
$32 million, while its revenues, after charging over $3,000 per test, were $222 million).
150. Cf. Wetkowski, supra note 10, at 183 (asserting that the United States has
surpassed other countries in the field of biotechnology because the reliability of
obtaining patents encourages investment).
151. See Lauren M. Dunne, Note, “Come, Let Us Return to Reason”: Association of
Molecular Pathology v. USPTO, 20 DEPAUL J. ART TECH. & INTELL. PROP. L. 473,
503-04 (2010) (contending that patents are not true monopolies because they are
limited in time, scope, and exercise).
152. See id. at 487 (elaborating that Myriad’s Comprehensive BRACAnalysis Test
costs approximately $3,000, while its BRACAnalysis Rearrangement Test costs around
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unable to receive secondary opinions because Myriad is the only laboratory
that can perform such testing.153
The most practical solution to the ostensible monopoly of patents on
gene sequences and correlative testing is to create a research exception.154
Currently, no other researchers have the right to use the gene sequence and
test in any manner.155 Under a research exemption, the patent grants the
inventor exclusive rights over his discovery or invention for a limited time,
but it would not preclude the use of the sequences to determine whether
scientists can obtain new information from the sequence, such that
Myriad’s testing could be improved.156 This exception would allow
Myriad to maintain exclusive commercial use of its patents, while serving
the common good of society by opening the field to collaborative research
by similar institutions.157 Because of the unclear status of gene patents,
Congress should legislate and uphold gene patents, while creating a
research exemption, such that researchers may coordinate their efforts in
furtherance of a societal good.158
V. CONCLUSION
The Southern District of New York erred in holding that (1) patents on
gene sequences are invalid because they are laws of nature, and (2) a
process of testing for breast cancer susceptibility is unpatentable because it
is not transformative and utilizes abstract ideas.159 Isolated, purified gene
$600).
153. See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181, 188-89 (S.D.N.Y. 2010) (citing Plaintiffs’ complaints that they cannot
afford the high costs charged by Myriad and discussing Myriad’s inability to receive
Medicaid coverage for its test).
154. See Hoffman, supra note 6, at 1037 (contending that a research exemption will
accomplish two goals of patent law: providing financial incentives and advancing the
body of scientific knowledge).
155. See Ass’n for Molecular Pathology, 702 F. Supp. 2d at 204-06 (referring to
instances whereby Myriad sought to enforce its patents through litigation).
156. See Whittemore v. Cutter, 29 F. Cas. 1120, 1121 (D. Mass. 1813) (doubting
that patent law was meant to punish one who uses a patent to satisfy mere curiosity);
see also Rebecca S. Eisenberg, Patents and the Progress of Science: Exclusive Rights
and Experimental Use, 56 U. CHI. L. REV. 1017, 1054 (1989) (adding that such access
to patents for research could be useful when the scientific community needs researchers
to challenge the theories and practices of their competitors).
157. See Eisenberg, supra note 156, at 1054-55 (explaining that cooperation among
the scientific community through “licensed access” to patents can help to reduce
research costs).
158. See Diamond v. Chakrabarty, 447 U.S. 303, 313 (1980) (implying that
Congress, not the courts, is the proper forum to balance the trade-offs and weigh
competing interests).
159. But see Ass’n for Molecular Pathology, 702 F. Supp. 2d at 218 (dismissing the
additional constitutional claims against the U.S. Patent & Trademark Office because
the patents were held invalid as claiming laws of nature).
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sequences are patentable subject matter because they have been removed
from all associated content and adjacent sequences.160 The gene sequences
then acquire a new utility for research and testing, which results solely
from the patentee’s manipulation.161 Moreover, diagnostic testing process
claims that analyze growth rates of cancerous DNA molecules are
patentable because the use of abstract mental processes of comparison and
analysis is sufficiently refined to cancer predisposition testing.162
Patents provide incentives to engage in and receive funding for research,
and prohibiting gene patents could destroy any and all incentives, thus
slowing the pace of the U.S. biotechnology industry.163 Courts should
continue to uphold Congress’s intended broad scope of patent law and
allow for the patentability of gene sequences, as such patents lead to great
advancements in medical research.164 Meanwhile, Congress should codify
the patentability of gene sequences and allow a research exemption, so as
to properly balance the trade-offs between the rewards and monopolies of
patents and weigh the competing interests of different sectors.165

160. See In re Bergstrom, 427 F.2d 1394, 1395-97 (C.C.P.A. 1970) (holding that an
isolated bodily composition was patentable because it was removed from associated
gland-tissue).
161. See Nowierski, supra note 12, at 503 (contending that patented sequences gain
specific functions after extensive experiments); cf. Parke-Davis & Co. v. H.K. Mulford
Co., 189 F. 95, 103 (S.D.N.Y. 1918) (illustrating that when Takamine removed
adrenalin from other gland tissue, the adrenalin was different in kind in that it acquired
commercially and therapeutically new uses).
162. See Gottschalk v. Benson, 409 U.S. 63, 71-72 (1972) (cautioning that a method
patent becomes a patent on an abstract principle when it entirely preempts a field of
research).
163. See Wetkowski, supra note 10, at 182 (arguing that the United States should
follow other countries by allowing gene patents).
164. See Bilski v. Kappos, 130 S. Ct. 3218, 3225 (2010) (explaining Jefferson’s
conception that ingenuity should receive liberal encouragement); cf. Hoffman, supra
note 6, at 1041-42 (suggesting that biotechnology patents should have a narrower
written description requirement so as to reduce conflict among those seeking to
improve upon inventions in the field).
165. See Hoffman, supra note 6, at 1030 (contending that biotechnology companies
are becoming increasingly private, thus creating a need to avoid a tragedy of the anticommons); see also Davis, supra note 146, at 323 (noting the Supreme Court’s ruling
that patents on living organisms are valid until prohibited by Congressional
legislation).
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